Recent News

• 03.31.2025 - OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod
• 03.10.2025 - OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain
• 02.12.2025 - OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod
• 01.31.2025 - OKYO Pharma Announces Chairman and CEO Acquire Shares
• 01.29.2025 - OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter
• 01.29.2025 - OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter
• 01.22.2025 - OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding
• 01.22.2025 - OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding

Recent Filings

• 03.31.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.31.2025 - EX-99.1 EX-99.1
• 03.18.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 03.10.2025 - EX-99.1 EX-99.1
• 03.10.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.12.2025 - EX-99.1 EX-99.1
• 02.12.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.31.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.31.2025 - EX-99.1 EX-99.1
• 01.29.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]